# A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

> **NCT06502366** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 422 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** BDA MDI HFO 160/180 μg
- **DRUG:** BDA MDI HFA 160/180 μg
- **DRUG:** Placebo MDI HFA

## Key facts

- **NCT ID:** NCT06502366
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-22
- **Primary completion:** 2026-03-03
- **Final completion:** 2026-03-03
- **Target enrollment:** 422 (ACTUAL)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06502366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06502366, "A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06502366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*